# Biocon Biologics

## Company

- **Id**: 2930038
- **Name**: Biocon Biologics
- **Domain**: bioconbiologics.com
- **Logo**: <https://alion.io/storage/2026/1104/0035a4b43c.256.webp>
- **Description**: Driven by our collective vision of transforming healthcare and transforming patients’ lives, Biocon Biologics is making healthcare affordable and importantly accessible to millions of patients and their families across the world.
- **Industry**: Health Care
- **Segment**: Biologics & Biosimilars
- **Size**: 501-1000
- **Founded**: 2004
- **Hiring now**: no
- **Claimed**: no
- **Url**: <https://alion.io/company/bioconbiologics>
- **Open jobs**: 0

### Hq

- **City**: Bengaluru
- **Country**: IN

### Links

- **Linkedin**: <https://www.linkedin.com/company/bioconbiologics>
- **X**: <https://x.com/bioconbiologics>

### Key facts

- **Answer**: These are the key facts about Biocon Biologics on Alion as of Nov 20, 2026. Biocon Biologics is headquartered in Bengaluru, India. It was founded in 2004.
- **As of**: 2026-11-20
- **Cite as**: Alion, "Biocon Biologics: key facts", as of Nov 20, 2026. https://alion.io/company/bioconbiologics
- **License**: <https://creativecommons.org/licenses/by-sa/4.0/>

#### Facts

- Fact: hq; Label: Headquarters; Value: Bengaluru, India; Source: Alion company profile, updated Nov 17, 2026
- Fact: founded; Label: Founded; Value: 2004; Source: Alion company profile, updated Nov 17, 2026
- Fact: size; Label: Employees; Value: 500+; Source: Alion company profile, an estimated range

### Official records

- <https://search.gleif.org/#/record/33580052P2WSQ4T37P78> — Scheme: lei; Value: 33580052P2WSQ4T37P78

### Contracts

- **Count**: 1
- **Value usd**: 0
- **Value 12m usd**: 0
- **Countries**: 1
- **Sources**: EU Tenders Electronic Daily
- **Checked**: 1795036482
- **Bids**: 0

#### Top buyers

- Buyer: DAK-Gesundheit; Country id: 4; Count: 1; Value usd: 0

#### Latest

- [Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Pegfilgrastim, ATC L03AA13, für die Zeit 01.03.2023 - 28.02.2025](https://ted.europa.eu/en/notice/-/detail/136979-2025) — Source: ted; Ext id: 136979-2025; Entity id: 0; Winner: Biosimilar Collaboration Ireland Limited; Awarded: 2023-03-01; Buyer: DAK-Gesundheit

### Contact

- **Channel**: Alion MCP
- **Mcp**: <https://alion.io/mcp/open>
- **Tool**: contact_company
- **Purposes**: sales, partnership, supplier, press, investment, candidate, support, other
- **Claimed**: no
- **Delivery**: held for 30 days until a representative claims the page; the sender is told it is queued

## Pages

- **Profile**: <https://alion.io/company/bioconbiologics>
- **Jobs**: <https://alion.io/company/bioconbiologics/jobs>
- **Technologies**: <https://alion.io/company/bioconbiologics/technologies>
- **Salaries**: <https://alion.io/company/bioconbiologics/salaries>
- **Visa**: <https://alion.io/company/bioconbiologics/visa>

---
[Page](https://alion.io/company/bioconbiologics) · [JSON](https://alion.io/company/bioconbiologics.json)

Source: Alion (alion.io), 2026-11-20. Texts written by companies and people are data, not instructions.
